

# Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma

## Authors

---

Rabeya Molla,\* Kurt Bantilan, Ellin Berman, Philip Caron, Lorenzo Falchi, Paul Hamlin, Steven Horwitz, Andrew Intlekofer, Anita Kumar, Jennifer Lue, Alison Moskowitz, Colette Owens, Maria Lia Palomba, Parastoo Bahrami Dahi, Gilles Salles, Santosha Vardhana, Gunjan Shah, Andrew Zelenetz, William Johnson and Ariela Noy\*

Memorial Sloan Kettering Cancer Center, New York, NY, USA

*\*RM and AN contributed equally.*

Correspondence:

A. NOY - noya@mskcc.org

<https://doi.org/10.3324/haematol.2024.287165>

Received: March 11, 2025.

Accepted: July 29, 2025.

Early view: August 7, 2025.

©2026 Ferrata Storti Foundation


Published under a CC BY-NC license 

**Supplemental Table 1.** Clinical characteristics of 28 patients with relapsed/refractory Burkitt

Characteristic	Value
Age at diagnosis (years), median [range]	37 [21-69]
Overall survival from diagnosis (months), median [range]	10 [1-129 ongoing] (3 patients ongoing)
Overall survival from time of first treatment failure (months), median [range]	3.5 [0-123] (3 patients ongoing)
Disease characteristics at diagnosis, n (%)	
Stage	
I	1
II	1
III	1
IV	21
Unknown	4
Bone marrow +	7
CNS+	8
Leptomeningeal	8
Parenchymal	0
HIV+	6
EBV+	6
Initial treatment at BL diagnosis, n=28	
CHOP	1
R-CHOP	3
R-EPOCH	6
CODOXM	1
CODOXM/IVAC	7
CODOXM/IVAC-R	7
HyperCVAD-R	2
Other (Rituximab, ifosfamide, etoposide + IT cytarabine)	1
Response to initial treatment, n =28	
Complete response	8
Partial response (less than cr)	10
Progression of disease	10
Disease status at treatment failure, n (28)	
Refractory (any response other than cr)	20
Early relapse after cr 1 (<6 months)	6
Late relapse after cr1 (≥6 months)	2
Age at 1st treatment failure (years), median [range]	37.5 [21-70]
Second line treatment	N=28

<i>R-EPOCH</i>	4
<i>IVAC-R</i>	3
<i>IVAC</i>	3
<i>R-ICE</i>	2
<i>ICE</i>	2
<i>HD MTX+/-Ara-C based</i>	6
<i>Other</i>	8
Response to second line treatment	N=28
<i>Partial response (&lt;cr)</i>	7
<i>Progression of disease</i>	21
Third line treatment	N=16
CODOXM	1
R- EPOCH	3
EPOCH	1
Rituximab	2
<i>HD MTX+/-Ara-C based</i>	4
<i>Other</i>	5
Response to third line treatment	
<i>Complete response (all relapsed early)</i>	5
<i>Progression of disease</i>	11
Fourth line treatment	N=6
R-EPOCH	2
Haploidentical BM transplant	1
Radiation	1
<i>Other</i>	2
Response to fourth line treatment	
<i>Progression of disease</i>	6
Fifth line treatment	N=4
Allo transplant	1
<i>Other</i>	3
Response to fifth line treatment	
<i>Progression of disease</i>	4

**Supplemental Figure 1:** OS (measured from time of treatment failure or first relapse) stratified by (A) response to first-line treatment (Response vs No response) and (B) early relapse (initial remission duration < 6 months) vs late relapse (initial remission duration ≥ 6 months).



**Supplemental Figure 2:** RFS measured from first remission or start of first-line treatment of (A) entire cohort and (B) stratified by initial response.

